Inducible Clindamycin Resistance in Staphylococci: Should Clinicians and Microbiologists be Concerned?

摘要: The increasing incidence of a variety infections due to Staphylococcus aureus--and, especially, the expanding role community-associated methicillin-resistant S. aureus (MRSA)--has led emphasis on need for safe and effective agents treat both systemic localized staphylococcal infections. Unlike most previously noted strains health care-associated MRSA, community-acquired MRSA isolates are often susceptible several non- beta -lactam drug classes, although they usually not macrolides. Several newer antimicrobial few older available treatment infections, but use may be limited by relatively high cost these or parenteral administration. Inexpensive oral localized, infection include clindamycin, trimethoprim-sulfamethoxazole, tetracyclines. Clindamycin has been used successfully pneumonia soft-tissue musculoskeletal in adults children. However, concern over possibility emergence clindamycin resistance during therapy discouraged some clinicians from prescribing that agent. Simple laboratory testing (e.g., erythromycin-clindamycin "D-zone" test) can separate have genetic potential (i.e., presence erm genes) become resistant fully clindamycin.